21 related articles for article (PubMed ID: 10369124)
1. The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production.
Woo J; Lemster B; Tamura K; Starzl TE; Thomson AW
Transplantation; 1993 Aug; 56(2):374-81. PubMed ID: 8356593
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine.
Thomson AW; Woo J; Lemster B; Todo S; Fung JJ; Starzl TE
Transplant Proc; 1993 Feb; 25(1 Pt 1):704-5. PubMed ID: 8438446
[No Abstract] [Full Text] [Related]
3. Immunotherapy for De Novo renal transplantation: what's in the pipeline?
Tedesco Silva H; Pinheiro Machado P; Rosso Felipe C; Medina Pestana JO
Drugs; 2006; 66(13):1665-84. PubMed ID: 16978033
[TBL] [Abstract][Full Text] [Related]
4. The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine.
Czech J; Kurrle R; Schorlemmer HU
Inflamm Res; 1999 Dec; 48 Suppl 2():S128-9. PubMed ID: 10667848
[No Abstract] [Full Text] [Related]
5. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
6. In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Schorlemmer HU; Kurrle R; Schleyerbach R; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S111-2. PubMed ID: 10667839
[No Abstract] [Full Text] [Related]
7. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro.
Barten MJ; Gummert JF; van Gelder T; Shorthouse R; Morris RE
J Immunol Methods; 2001 Jul; 253(1-2):95-112. PubMed ID: 11384672
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of new immunosuppressants.
Halloran PF
Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay.
Slauson SD; Silva HT; Sherwood SW; Morris RE
Immunol Lett; 1999 Apr; 67(3):179-83. PubMed ID: 10369124
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
